Analyze Your Search

Hints:

  • Action links for each search result record
    • Bookmark: Allows you to Bookmark the page for easy future retrieval 
    • Email: Opens a pop-up window where you can write a message to the recipient of the email
    • Copy URL: Copies the URL of the requested document for pasting in an email or other document
    • More Info: Shows full summary of content record
  • Saved Searches and Alerts
    • Save your search for later viewing & updates by clicking the blue "Follow" button to the right of the search box. 
Prostate Cancer
  Follow Topic   Edit Search
Your search returned 12 results
from the time period: last 30 days.
Sort by Relevance / Date Group By Journal / No Grouping
European journal of cancer (Oxford, England : 1990) 
AbstractText: Cabazitaxel (CBZ), a novel tubulin-binding taxane, improves overall survival in metastatic castration-resistant prostate cancer (mCRPC) that progresses during or after docetaxel treatment... Keyword: Castration-resistant prostate cancer. Keyword: Circulating tumour cells. Keyword: Dosing schedule. Keyword: Toxicity.
Oncology (5)
Prostatic Neoplasms (3), Neutropenia (2), Leukopenia (1), more mentions
BMJ (Clinical research ed.) 
DescriptorName: Prostatic Neoplasms... Genetic and Epidemiology of Colorectal Cancer Consortium (GECCO), and the Prostate Cancer Association Group to Investigate Cancer Associated Alterations in the Genome ... and the MR-Base platform).Participants 70 563 cases of cancer (22 898 prostate cancer, 15 748 breast cancer, 12 537 lung cancer, 11 488 ...
Oncology (21)
Neoplasms (8), Colorectal Neoplasms (4), Prostatic Neoplasms (4), more mentions
European urology 
... specific antigen (PSA) has led to an early detection of prostate cancer (PCa) and a reduction of metastatic disease at diagnosis, PSA ... In men with previous negative pathological findings, Prostate Cancer Antigen 3 and ConfirmMDx predicted the outcome of subsequent biopsy ... the efficacy and cost utility of these new technologies AbstractText: Prostate cancer is a heterogeneous disease with a wide variability.
Oncology (5)
Prostatic Neoplasms (5), Neoplasms (2), more mentions
JAMA oncology 
AbstractText: Androgen receptor-signaling inhibitor (ARSi) drugs prolong life in metastatic castration-resistant prostate cancer (mCRPC), but such tumors eventually become resistant and progress... Image-directed biopsy determined the presence or absence of prostate cancer at positive imaging sites AbstractText: PET/CT imaging was performed with [18F]-FDHT and [18F ...
Oncology (4)
Prostatic Neoplasms (3), Neoplasms (2), more mentions
International journal of cancer 
... present study investigates whether intake of these compounds may influence prostate cancer risk in human populations... median follow up of 11.5 years, 2,598 cases of prostate cancer (including 287 advanced cases) have been identified among 27,004 ... intervals (CI) for dietary isoflavones and coumestrol in relation to prostate cancer risk.
Oncology (11)
Prostatic Neoplasms (8), Ovarian Neoplasms (2), Neoplasms (1), more mentions
European urology 
... incidence were found AbstractText: For patients with GS ≥7 receiving SRT, clinicians should weigh FFBF benefits of WPRT and ADT against toxicities. Future studies should explore the impact of WPRT on quality of life, clinical progression, and overall survival AbstractText: We evaluated patients with prostate cancer treated with radiation after surgery to remove the prostate... Keyword: Prostate cancer. Keyword: Prostatectomy.
Oncology (4)
Prostatic Neoplasms (3), Neoplasms (1), more mentions
European urology 
... standard of care in fit men with metastatic castration-naive prostate cancer (mCNPC) following results from GETUG-AFU 15, CHAARTED, and STAMPEDE ... on the efficacy of treatments used for metastatic castration-resistant prostate cancer (mCRPC) in men treated upfront with ADT plus docetaxel for ... treated upfront with chemo-hormonal therapy for metastatic castration-naive prostate cancer.
Oncology (5)
Prostatic Neoplasms (5), more mentions
Annals of oncology : official journal of the European Society for Medical Oncology 
AbstractText: Genomic aberrations have been identified in metastatic castration-resistant prostate cancer (mCRPC), but molecular predictors of resistance to abiraterone acetate/prednisone (AA/P) treatment are not known AbstractText: In a prospective clinical trial, mCRPC patients underwent whole exome sequencing (n = 82) and RNA-sequencing ... Keyword: Castrate-resistance prostate cancer.
Oncology (3)
Prostatic Neoplasms (3), more mentions
European urology 
Abstract: Addition of docetaxel to androgen deprivation therapy (ADT) was recommended for patients with newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC), who are fit enough to receive docetaxel. Two recently published trials showed that the addition of abiraterone acetate plus prednisone to ADT has a clear survival benefit and acceptable overall tolerance, and should be considered as another standard ...
Oncology (2)
Prostatic Neoplasms (2), more mentions
Advances in radiation oncology 
AbstractText: Moderately hypofractionated intensity modulated radiation therapy (HIMRT) for prostate cancer shortens the treatment course while providing outcomes comparable with those ... level data from a randomized trial AbstractText: Men with localized prostate cancer were randomized to CIMRT (75.6 Gy in 42 fractions over ... AbstractText: HIMRT is more cost-efficient than CIMRT for treating prostate cancer, even when taking into account the costs related to late ...
Oncology (3)
Prostatic Neoplasms (3), more mentions
Nature communications 
... ichorCNA, software that quantifies tumor content in cfDNA from 0.1× coverage whole-genome sequencing data without prior knowledge of tumor mutations. We apply ichorCNA to 1439 blood samples from 520 patients with metastatic prostate or breast cancers. In the earliest tested sample for each patient, 34% of patients have ≥10% tumor-derived cfDNA, sufficient for standard coverage whole-exome sequencing.
Neoplasms (9), more mentions
European urology 
... use of [(18)F]- and [(68)Ga]-labeled inhibitors of prostate-specific membrane antigen (PSMA) for positron emission tomography (PET) imaging of prostate cancer is now widespread... is a framework for classifying PSMA-targeted PET scans and individual findings into categories that reflect the likelihood of the presence of prostate cancer.
Oncology (2)
Prostatic Neoplasms (2), more mentions